|
|
 |
November 13, 2007 |
Now Available: Video Podcasts of MSK Report's Meeting Coverage
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
ACR 2007: Visit Musculoskeletal Report's dedicated ACR 2007 page for complete coverage of the American College of Rheumatology's 71st Annual Scientific Meeting, including press conference videos and interviews with presenters.
ACR 2007: More Fallout From the COX-2 Debacle: Increasing Rates of Serious GI Complications
Physicians need to be more vigilant about prescribing proton pump inhibitors (PPIs) to their arthritis patients who take traditional nonsteroidal anti-inflammatory drugs (NSAIDs), because the number of serious gastrointestinal complications is on the rise since the COX-2 drugs fell from grace...
ACR 2007: Rheumatologists Optimistic About IL-6 Blocker Tocilizumab
The interleukin-6 (IL-6) blocker tocilizumab is safe, effective, and improves quality of life for rheumatoid arthritis (RA) patients...
ACR 2007: Single Botulinum Toxin Injection Smooths Out OA Shoulder Pain
A single intra-articular injection of botulinum toxin type A relieved shoulder pain for a month in patients with refractory OA...
ACR 2007: Infliximab Adds Little to Combined DMARDs for Early RA--Unless You're Fat
Obesity halves an RA patient¡¯s chance of remission with conventional combination DMARD treatment, but adding infliximab can overcome this problem...
ACR 2007: Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...
ACR 2007: Rheumatologists Need to Be More Shoe Savvy
Clogs and stability shoes are good for the feet but not the knees of patients with knee OA...
BioPharm Business: Targeted Genetics Reports Positive Interim Phase I/II Results for tgAAC94 in Inflammatory Arthritis; Tests Indicate tgAAC94 Did Not Contribute to Immunosuppression Leading to Fatal SAE
Targeted Genetics Corp, a clinical-stage biotechnology company, announced that interim data from its phase I/II trial of tgAAC94 for inflammatory arthritis suggest that the investigational therapy showed improvement in patient-reported outcome measures...
BioPharm Business: Biogen Idec's Baminercept, the First Lymphotoxin-¦Â Pathway Inhibitor in Development, Shows Promise in Phase IIa Trial in RA Patients; Phase IIb Underway
Biogen Idec announced results from its phase IIa trial of baminercept, the first dual-mechanism, lymphotoxin-¦Â (LT-¦Â) and LIGHT pathway inhibitor in development for the treatment of autoimmune diseases...